Next Article in Journal
Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges
Next Article in Special Issue
Targeting XIAP for Promoting Cancer Cell Death—The Story of ARTS and SMAC
Previous Article in Journal
Differential Sensitivity of Two Endothelial Cell Lines to Hydrogen Peroxide Toxicity: Relevance for In Vitro Studies of the Blood–Brain Barrier
Previous Article in Special Issue
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Open AccessReview

Future Therapeutic Directions for Smac-Mimetics

by 1,2, 1,2 and 1,2,*
1
Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne VIC 3052, Australia
2
Department of Medical Biology, University of Melbourne, Melbourne VIC 3010, Australia
*
Author to whom correspondence should be addressed.
Cells 2020, 9(2), 406; https://doi.org/10.3390/cells9020406
Received: 21 January 2020 / Revised: 5 February 2020 / Accepted: 7 February 2020 / Published: 11 February 2020
(This article belongs to the Special Issue Inhibitor of Apoptosis Proteins (IAPs) in Cancer Therapy)
It is well accepted that the ability of cancer cells to circumvent the cell death program that untransformed cells are subject to helps promote tumor growth. Strategies designed to reinstate the cell death program in cancer cells have therefore been investigated for decades. Overexpression of members of the Inhibitor of APoptosis (IAP) protein family is one possible mechanism hindering the death of cancer cells. To promote cell death, drugs that mimic natural IAP antagonists, such as second mitochondria-derived activator of caspases (Smac/DIABLO) were developed. Smac-Mimetics (SMs) have entered clinical trials for hematological and solid cancers, unfortunately with variable and limited results so far. This review explores the use of SMs for the treatment of cancer, their potential to synergize with up-coming treatments and, finally, discusses the challenges and optimism facing this strategy. View Full-Text
Keywords: Smac/DIABLO; Smac-Mimetics; IAPs; TNF; cell death; cancer Smac/DIABLO; Smac-Mimetics; IAPs; TNF; cell death; cancer
Show Figures

Figure 1

MDPI and ACS Style

Morrish, E.; Brumatti, G.; Silke, J. Future Therapeutic Directions for Smac-Mimetics. Cells 2020, 9, 406. https://doi.org/10.3390/cells9020406

AMA Style

Morrish E, Brumatti G, Silke J. Future Therapeutic Directions for Smac-Mimetics. Cells. 2020; 9(2):406. https://doi.org/10.3390/cells9020406

Chicago/Turabian Style

Morrish, Emma; Brumatti, Gabriela; Silke, John. 2020. "Future Therapeutic Directions for Smac-Mimetics" Cells 9, no. 2: 406. https://doi.org/10.3390/cells9020406

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop